CLAIMS:

1. A formulation for treating a disease or disorder treatable by an agonist of the A3 adenosine receptor (A_3AR), comprising an amount of at least one cannabinoid effective to treat or ameliorate said disease or disorder.

2. The formulation of claim 1, wherein said cannabinoid exerts it effect primarily through the A_3AR.

3. The formulation of claim 1 or 2, wherein said cannabinoid has a physiological effect or therapeutic effect on said disease or disorder that is reduced by an antagonist of the A_3AR.

4. The formulation of any one of claims 1 to 3, wherein the at least one cannabinoid has an A_3AR activator effect.

5. The formulation of claims 4, wherein the at least one cannabinoid has an A_3AR agonistic activity.

6. The formulation of any one of claims 1 to 5, wherein the disease or disorder is associated with an elevated level of expression of an A_3AR in cells or tissue, as compared to cells or tissue of the same lineage in subjects not suffering from said or disorder.

7. The formulation of any one of claims 1 to 6, wherein the disease or disorder is cancer, inflammatory disease, liver disease such as NAFLD or obesity.

8. The formulation of any one of claims 1 to 7, comprising at least one cannabinoid selected from the group consisting of: (i) tetrahydrocannabinolic acid (THCA), tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV); (ii) chemical derivatives of the cannabinoids of (i); and (iii) an extract of cannabis plant.

9. The formulation of any one of claims 1 to 8, comprising also an activator of the A_3AR.

10. The formulation of claim 9, wherein said activator is an A_3AR agonist.

11. A cannabinoid for treating a disease or disorder treatable by an agonist of the A3 adenosine receptor (A_3AR).

12. The cannabinoid of claim 11, exerting it effect primarily through the A_3AR.

13. The cannabinoid of claim 11 or 12, having a physiological effect or therapeutic effect on said disease or disorder that is reduced by an antagonist of the A_3AR.

14. The cannabinoid of claim 13, having an A_3AR activator effect.

15. The cannabinoid of claim 14, having an A_3AR agonistic activity.

16. The cannabinoid of any one of claims 11 to 15, wherein the disease or disorder is associated with an elevated level of expression of an A_3AR in cells or tissue, as compared to cells or tissue of the same lineage in subjects not suffering from said or disorder.

17. The cannabinoid of claim 16, wherein the disease or disorder is cancer, inflammatory disease, liver disease such as NAFLD or obesity.

18. The cannabinoid of any one of claims 11 to 17, being one or more of the group consisting of: (i) tetrahydrocannabinolic acid (THCA), tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV); (ii) chemical derivatives of the cannabinoids of (i); and (iii) an extract of cannabis plant.

19. The cannabinoid of any one of claims 11 to 18, for administration in combination with an activator of the A_3AR.

20. The cannabinoid of claim 19, wherein said activator is an A_3AR agonist.

21. A method of treating a disease or disorder treatable by an agonist of the A3 adenosine receptor (A_3AR), comprising administering to a subject having said disease or condition at least one cannabinoid in an amount effective to improve said disease or disorder or a condition exhibited by the subject as a result of said disease or disorder.

22. The method of claim 21, wherein said cannabinoid exerts it effect primarily through the A_3AR.

23. The method of claim 21 or 22, wherein said cannabinoid has a physiological effect or therapeutic effect on said disease or disorder that is reduced by an antagonist of the A_3AR.

24. The method of any one of claims 21 to 23, wherein the at least one cannabinoid has an A_3AR activator effect.

25. The method of claims 24, wherein the at least one cannabinoid has an A_3AR agonistic activity.

26. The method of any one of claims 21 to 25, wherein the disease or disorder is associated with an elevated level of expression of an A_3AR in cells or tissue, as compared to cells or tissue of the same lineage in subjects not suffering from said or disorder.

27. The method of any one of claims 21 to 26, wherein the disease or disorder is cancer, inflammatory disease, liver disease such as NAFLD or obesity.

28. The method of any one of claims 21 to 27, comprising administering to the subject at least one cannabinoid selected from the group consisting of: (i) tetrahydrocannabinolic acid (THCA), tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV); (ii) chemical derivatives of the cannabinoids of (i); and (iii) an extract of cannabis plant.

29. The method of any one of claims 21 to 28, comprising also an activator of the A_3AR.

30. The method of claim 29, wherein said activator is an A_3AR agonist.

31. A method of treating a disease or disorder in a subject, comprising obtaining data on level of expression A3AR in tissue or cells of the subject; and when said data is indicative that expression level is elevated as compared to level of expression of the A3AR on cells or tissue of same lineage in subjects not suffering from said disease or condition, administering to the subject at least one cannabinoid in an amount effective to achieve improvement in said disease or condition.

32. The method of claim 31, wherein said cannabinoid exerts it effect primarily through the A_3AR.

33. The method of claim 31 or 32, wherein said cannabinoid has a physiological effect or therapeutic effect on said disease or disorder that is reduced by an antagonist of the A_3AR.

34. The method of any one of claims 31 to 33, wherein the at least one cannabinoid has an A_3AR activator effect.

35. The method of claims 34, wherein the at least one cannabinoid has an A_3AR agonistic activity.

36. The method of any one of claims 31 to 35, wherein the disease or disorder is associated with an elevated level of expression of an A_3AR in cells or tissue, as

compared to cells or tissue of the same lineage in subjects not suffering from said or disorder.

37. The method of any one of claims 31 to 36, wherein the disease or disorder is cancer, inflammatory disease, liver disease such as NAFLD or obesity.

38. The method of any one of claims 31 to 37, comprising administering to the subject at least one cannabinoid selected from the group consisting of: (i) tetrahydrocannabinolic acid (THCA), tetrahydrocannabinol (THC), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV); (ii) chemical derivatives of the cannabinoids of (i); and (iii) an extract of cannabis plant.

39. The method of any one of claims 31 to 38, comprising also an activator of the A_3AR.